Navigation Links
Abbott Statement: ACCORD Lipid Results Support Treatment Guidelines for Fibrate Use
Date:3/14/2010

ATLANTA, March 14 /PRNewswire-FirstCall/ -- Results were presented today on behalf of the National Heart, Lung and Blood Institute from ACCORD, a study in patients with diabetes that evaluated cardiovascular outcomes in three distinct studies – glycemic control, blood pressure control and lipid control.  In response to data from the ACCORD Lipid study, Abbott issued the following statement:

"The results of ACCORD Lipid were widely expected and not surprising given that two-thirds of patients in the trial would not be treated with fibrates under current guidelines," said Eugene Sun, M.D., vice president, Global Pharmaceutical Development, Abbott.  "While the primary endpoint of the study was not met, the pre-specified subgroup of patients with high triglycerides and low HDL showed potential benefit.  In these patients, fenofibrate plus simvastatin was associated with a 31 percent lower rate of heart attack, stroke and cardiovascular death than simvastatin alone."

The average triglyceride level of a patient that starts fenofibrate in the United States is 302 mg/dL, according to medical claims data.  The median triglyceride level in ACCORD Lipid was 162 mg/dL.  The subgroup of patients in this study with triglycerides at or above 204 mg/dL reflects real-world fibrate usage.

"We are encouraged by the overall safety reported in the ACCORD Lipid study for fenofibrate," added Sun.  "The results are consistent with the safety shown in other studies and support how fibrates are used in treatment today based on guideline recommendations."

The National Cholesterol Education Program (NCEP) treatment guidelines recommend using fibrates with statins in patients with triglycerides above 200 mg/dL when the LDL goal has been met.  

The primary endpoint for ACCORD Lipid (n = 5,518) compared fenofibrate plus simvastatin to simvastatin alone on cardiovascular outcomes of heart attacks, strokes and cardiovascular death.  There was no statistical difference in the primary outcome between the two treatment groups (p = 0.32).  In a pre-specified sub-group of patients with both high triglycerides (at or above 204 mg/dL) and low HDL (at or below 34 mg/dL), there was a 31 percent lower rate of cardiovascular events in the fibrate-plus-statin arm compared to the statin-only arm (p = 0.057 for interaction).

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs approximately 83,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

SOURCE Abbott

Back to top

RELATED LINKS
http://www.abbott.com

'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data Demonstrates Abbotts Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition
2. Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer
3. Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy
4. Abbott to Present at Cowen and Company Annual Health Care Conference
5. Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets
6. Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval
7. Abbott and Pierre Fabre SA Announce Collaboration to Research and Develop Novel Treatments for Cancer
8. Abbotts Ibis Technology Named One of the Top Innovations for 2009 by The Scientist
9. The Deal Names Abbott Top Dealmaker for Second Consecutive Year
10. Abbott Completes Visiogen Acquisition
11. Abbott Cuts Use of Oil and Coal by 35 Percent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)...   ZirMed Inc ., a recognized leader in cloud-based ... has been ranked #1 by its users for the seventh ... User Survey. ZirMed was recognized as the top-ranked end-to-end revenue ... centers over 200 beds and holds one of the longest ... history. ...
(Date:9/18/2017)... R.I. , Sept. 18, 2017 /PRNewswire/ ... the fields of bioinformatics and immune engineering, ... a protective avian influenza A (H7N9) vaccine. ... distantly related to seasonal influenza and presents ... rely on prior exposure to be effective. ...
(Date:9/12/2017)... Sept. 12, 2017   EcoVadis , the leading platform for environmental, ... first annual edition of its Global CSR Risk and Performance Index. The ... EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points across ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian ... On The Brink” is the creation of published author, William Nowers. Captain Nowers ... a WWII veteran, he spent thirty years in the Navy. Following his career ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
Breaking Medicine News(10 mins):